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Summary 
Allograft rejection is a T cell-dependent process. Productive T cell activation by antigen requires 
antigen engagement of the T  cell receptor as well as costimulatory signals delivered through 
other T cell surface molecules such as CD28. Engagement of CD28 by its natural ligand B7 
can be blocked using a soluble recombinant fusion protein, CTLA4Ig. Administration of CTLA4Ig 
blocks antigen-specific immune responses in vitro and in vivo, and we have shown that treatment 
of rats with a 7-d course of CTLA4Ig at the time of transplantation  leads to prolonged survival 
of cardiac allografts (median 30 d), although most grafts are eventually rejected. Here, we have 
explored additional strategies employing CTLA4Ig in order to achieve  long-term allograft survival. 
Our data indicate that donor-specific  transfusion (DST) plus CTLA4Ig can provide effective  antigen- 
specific immunosuppression. When DST is administered at the time of transplantation followed 
by a single dose of CTLA4Ig 2 d later, all animals had long-term graft survival (>60 d). These 
animals had delayed responses to donor-type skin transplants,  compared with normal rejection 
responses to third-party skin transplants. Furthermore, donor-matched second cardiac allografts 
were well tolerated  with minimal histologic evidence of rejection.  These data  indicate  that 
peritransplant use of DST followed by subsequent treatment with CTLA4Ig can induce prolonged, 
often indefinite, cardiac allograft acceptance. These results may be clinically applicable for cadaveric 
organ and tissue transplantation  in humans. 
I 
nduction of a T cell immune response is required for al- 
lograft rejection (1). Antigen-specific T cell activation is 
initiated through the TCR (2). However, recent evidence has 
shown that T cells require two signals for activation (3): signal 
1, which is provided by stimulation through the TCR, and 
signal 2 (costimulation), which can be provided by ligation 
of one or more T cell surface receptors. Engagement of the 
TCR receptor alone (i.e., signal 1 without signal 2) has been 
reported to induce a long-lasting state of T cell anergy, ren- 
dering cells unresponsive  to subsequent  antigenic stimula- 
tion (3). 
The best characterized costimulatory pathway is transduced 
through the CD28 surface molecule. CD28 is a receptor for 
B7, a molecule that can be expressed by many types of APCs 
(4). Stimulation of CD28 by its ligand B7 provides sufficient 
costimulatory signals to TCtL-activated Tcens for lymphokine 
production and cell proliferation (5). CTLA-4 is a gene closely 
related to CD28 which also serves as a B7-1igand, although 
the physiologic role of this interaction is not yet defined (6). 
Recently, a soluble recombinant protein termed CTLA4Ig 
was produced, which contains  the extracellular domain of 
human CTLA-4 fused to a human Ig C3' chain (6). CTLA4Ig 
displays an •20-fold  higher affinity for B7 than does CD28 
(6), therefore acting as a competitive inhibitor of CD28 en- 
gagement. Although constructed using the human CTLA-4 
domain, CTLA4Ig binds efficiently to murine and rat B7. 
CTLA4Ig inhibits B7-dependent immune responses in vitro 
(6). In vivo, CTLA4Ig blocks T cell-dependent B cell anti- 
body production, and prevents the rejection of xenogeneic 
islet and allogeneic cardiac allografts (7-9). In the studies of 
cardiac allograft rejection we found that animals treated with 
daily injections  of CTLA4Ig for 7 d, initiated at the time 
of transplantation,  had greatly prolonged graft survival (me- 
dian 30 d, versus 7 d for control animals),  although most 
animals eventually rejected the graft (7). Pretransplant thymec- 
tomy did not further extend survival in CTLA4Ig-treated 
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time of transplantation eventually recovered the capacity to 
induce rejection. 
In  this  report  we have explored other  strategies  using 
CTLA4Ig in order to achieve consistent long-term allograft 
survival.  We find that donor-specific cell transfusion (DST) 
at the time of transplantation, followed by a single dose of 
CTLA4Ig 2 d later, is sufficient to lead to prolonged, often 
indefinite, cardiac allograft survival.  Since no treatment is re- 
quired before transplantation, these results may be clinically 
applicable for cadaveric organ and tissue transplantation in 
humans. 
Materials  and Methods 
Animals.  The experiments were conducted using inbred male 
Lewis (LEW, RTll), Brown Norway (BN, RT1 n) and ACI (RT1  ~) 
rats weighing 200-300 g (Harlan Sprague  Dawley,  Inc., Indianapolis, 
1N). LEW rats served as heterotopic cardiac allograft recipients. 
BN and ACI rats were used as cardiac and skin allograft donors, 
and as a source of splenocytes for DST. 
Splenocyte Transfusion.  Spleens  were harvested and a single cell 
suspension prepared as previously  described (7). Red cells were lysed 
with water, and the remaining population  of mononuclear cells 
was washed two times in RPMI-1640. Cell viability was consis- 
tently >95%  as determined by trypan  blue exclusion. Varying 
numbers of splenocytes were injected intravenously in a volume 
of 0.5-1.0 ml into anesthetized rats at the indicated time points. 
Cardiac Transplantation.  The rats were anesthetized and mechan- 
ically ventilated, after which donor hearts were transplanted into 
a cervical location in the recipient animals (10). Allograft survival 
was assessed by daily palpation. The day of rejection was defined 
as the day of cessation of palpable heartbeat, and verified by au- 
topsy and selective pathological examination. Loss of graft func- 
tion within 48 h of transplant was considered a technical failure 
(<5% on the average), and these animals were omitted from fur- 
ther analysis. 
Skin Grafting.  Animals  with long-term (;>60 d) cardiac allograft 
survival received donor-specific and third-party skin grafts placed 
simultaneously on alternate sides of the flanks. Donor skin was 
raised as full-thickness grafts  from the center abdominal wall, 
trimmed of fat, cut into standard sizes (2 cm circular skin), and 
sutured into position as described (11). The grafts were inspected 
daily, and rejection was said to have occurred when more than 50% 
of the graft surface became raised, necrotic, or covered by eschar. 
Mixed Lymphocyte Reaction (MLR).  Lymphocytes  were isolated 
from cervical and axillary nodes by gentle passage of tissue through 
a nylon mesh. Cells were cultured in RPMI-1640 medium sup- 
plemented  with  5  mM  Hepes, penicillin  (10  s U/liter),  strep- 
tomycin (100 #g/liter), 50/~M 2-ME, and 10% FCS (GIBCO BRL, 
Gaithersburg, MD). Next, 3  x  10  s each of responder cells and 
irradiated (3,000 tad; 13rCs source) stimulator cells were cocultured 
for 4 d in 96-we11 flat-bottomed microtiter plates as described (7). 
Proliferation,  measured as DNA synthesis, was determined by 
adding 1/~Ci of [3H]thymidine  (ICN Radiochemicals, Irvine, CA) 
to each well for the last 6 h of culture. All assays were performed 
in quadruplicate. 
Results and Discussion 
In  our  initial  studies,  we  found  that  a  7-d  course  of 
CTLA4Ig administered to cardiac allograft recipients starting 
at the time of transplantation significantly prolonged allograft 
survival but did not prevent eventual rejection (7). As prior 
thymectomy failed to induce permanent engraftment in treated 
animals, T cells present during the course of CTLA4Ig ad- 
ministration were responsible for rejection. We hypothesized 
that the kinetics of T  cell trafficking might not permit all 
alloreactive cells to encounter donor antigens in the graft or 
regional lymphoid tissue during the 7-d period of drug ad- 
ministration, and that T cells that escaped an encounter with 
antigen in the context of B7-blockade could eventually reject 
the graft. Therefore, we first extended the period of CTLA4Ig 
treatment. However, animals receiving daily CTLA4Ig for 
21 d rejected their grafts at the same time points as those 
treated for only 7 d  (data not shown). 
We next considered the possibility that immunosuppres- 
sion  would be  most  effective if the alloantigen were ad- 
ministered systemically in conjunction with CTLA4Ig,  so 
as to expose all T cells throughout the body to antigen during 
the drug treatment period. For example, treatment of mice 
with CTLA4Ig blocks the immune response to systemically 
administered antigens such as sheep RBCs or KLH (8). There- 
fore, LEW  animals received 10  s BN  lymphocytes intrave- 
nously (DST) plus a single dose of CTLA4Ig (0.5 mg) 14 d 
before placement ofa BN cardiac allograft. As shown in Table 
1, animals treated with this protocol had significant prolon- 
gation of cardiac allograft survival,  with median graft sur- 
vival of 17 d. This effect required both DST and CTLA4Ig, 
as animals treated with either alone rejected their grafts by 
8 d. Furthermore, immunosuppression by DST plus CTLA4Ig 
was antigen specific. Animals receiving transfusions from third- 
party ACI animals had a median graft survival of only 9 days. 
Conversely, when ACI animals were used as heart donors, 
DST from ACI animals synergized with CTLA4Ig to pro- 
long graft survival (>/20 d), whereas transfusions from BN 
animals had no effect (rejection by day 7).  These data also 
indicate that CTLA4Ig is not merely acting by depleting the 
graft of B7 + APCs. First,  strain-specific cell transfusions are 
required for the immunosuppressive effect. Second, our prior 
analysis of CTLA4Ig pharmacokinetics indicated a serum half- 
life of 2.8 d (7), and therefore by the time of transplantation 
circulating CTLA4Ig levels would have fallen far below a ther- 
apeutic level. 
We had initially chosen to administer CLTA4Ig plus DST 
14 d before transplantation because of the possibility that it 
might take several days after exposure to this regimen for a 
state of antigen-specific nonresponsiveness to develop. How- 
ever, although graft survival was significantly prolonged in 
animals treated with this protocol, eventually most grafts were 
rejected. Therefore, we next considered whether a state of 
tolerance was being induced, but that this state was temporary, 
and had largely waned by 2 wk. This concept was supported 
by two sets of data. First, in studies of anergy induction in 
T cell clones, anergy, although reproducible, was not a per- 
manent state, as the cells could spontaneously regain respon- 
siveness after a finite period of time (12). Second, recent in 
vivo studies have demonstrated that maintenance of anergy 
requires the persistence of antigen (13).  Thus we reasoned 
that induction of anergy by DST plus CTLA4Ig might best 
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Heart donor  DST donor  DST day  CTLA4Ig day  Graft  survival 
d 
BN  None  5,7,7,7,7,7,7,7,7,7 
BN  BN  -  14  6,6,7,7,8,8 
BN  None  -  14  6,8,8 
BN  BN  -  14  -  14  14,14,15,16,17,19,46,>100 
BN  ACI  -  14  -  14  7,8,9,9,10,13 
ACI  None  5,5,6,7,8 
ACI  ACI  -  14  -  14  23,26,58,>100 
ACI  ACI  -  14  None  1,2,5,5,6,7 
ACI  BN  -  14  -  14  6,6,7,7,7 
Allograft recipients were LEW  animals,  some of which received DST  (10  s cells) via intravenous injection, CTLA4Ig  (0.5 mg) by intraperitoneal 
injection,  or both  14 d  before  transplantation as  indicated.  The  day of transplantation was  defined as  day 0. 
prolong graft survival if transplantation was performed simul- 
taneously. However, when CTLA4Ig plus DST  (4  x  10  7 
ceils) were administered on the day of transplantation, graft 
survival was not improved over the previous protocol, and 
was no different than in animals treated with a single dose 
of CTLA4Ig without DST (Table 2). 
At present, knowledge of the target of action of CTLA4Ig 
is limited.  Its only known ligand is B7, whose expression 
is restricted to cells of hematopoietic origin, in particular those 
which can serve as APCs. In the case of vascularized organ 
allografts, there are two routes of alloantigen presentation 
using distinct APCs (14,  15).  In the indirect route, donor 
alloantigens,  shed from the surface of donor parenchymal cells, 
are presented by host APCs in regional LNs.  In the direct 
route, APCs resident within the graft directly stimulate host 
T cells. Although the relative contribution of these two routes 
is the subject of debate, the importance of direct sensitiza- 
tion has been demonstrated by the fact that graft survival 
is significantly prolonged by depleting tissues and organs of 
resident APCs (for a review see reference 16). In this regard, 
it is notable that whereas a short course of CTLA4Ig fre- 
quently induced indefinite survival of human islet xenografts 
in mice, anti-human B7 antibody was effective as well, indi- 
cating that much of the immune response was initiated against 
donor-type APCs (9). 
One of the most potent types of APC known is the den- 
dritic cell (17). Compared with activated B cells and macro- 
phages, extremely small numbers of dendritic cells are sufficient 
to stimulate T cell responses. Furthermore, in contrast to B 
cells and macrophages, dendritic cells constitutively express 
B7 (18, 19). Larsen et al., (20) have shown that after cardiac 
allograft placement, donor dendritic cells migrate into host 
lymphoid organs, and it is possible that this may be respon- 
sible for initiating graft rejection. The migration of dendritic 
cells to LNs was found to peak 2 d after transplantation.  There- 
fore, we next administered DST (4  x  10  7 cells) on the day 
of transplantation,  followed by a single dose of CTLA4Ig 
2 d later (Table 2).  Whereas DST alone was not immuno- 
Table  2.  Effects of Peri-transplant DST plus CTLA4Ig  on Cardiac Allografi Survival 
DST donor  DST day  CTLA4Ig day  Graft  survival 
d 
--  --  --  5,7,7,7,7,7,7,7,7,7 
BN  0  -  7,7,9,10,11 
-  -  0  8,10,18 
BN  0  0  8,11,19 
-  -  2  8,14,17,25,28 
BN  0  2  89,>100,>100,>100,>100 
ACI  0  2  14,23,26,28,56 
Allograft recipients were LEW animals and heart donors were BN animals. Selected recipient animals received DST (4  x  107 cells) via intravenous 
injection,  CTLA41g  (0.5  rag)  by intraperitoneal injection,  or both at the times indicated.  The day of transplantation was  defined  as  day 0. 
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Functioning Cardiac Allografts 
Skin graft survival 
Day of  BN  Third-party 
Animal  skin grafting  skin  (ACI) skin 
1  64  19  10 
2  64  19  10 
3  66  22  9 
4  72  19 
5  83  19 
Skin graft  recipients were LEW animals that had received BN cardiac 
allografrs and immunosuppression with DST plus CTLA4Ig. Skin grafts 
from donor-strain animals (BN) and from third-party animals were per- 
formed simultaneously on the indicated day after cardiac transplantation. 
suppressive, and CTLA4Ig by itself had a modest effect on 
graft survival, the combination reproducibly induced long- 
term engraftment. Similar to pretransplantation  DST plus 
CTLA4Ig (Table 1), the immunosuppressive effect of this pro- 
tocol was also antigen specific,  as LEW rats that received  trans- 
fusions from ACI animals rejected BN cardiac allografts at 
a median of 26 d. 
Additional transplants  were performed on these animals 
with stable aUografts. Skin transplants from donor-type BN 
animals or from third-party ACI animals were simultaneously 
placed on opposite flanks (Table 3). The ACI grafts were all 
rejected by 10 d, the normal time for rejection of ACI skin 
grafts in LEW animals. In contrast, the BN grafts survival 
for a median of 19 d. This demonstrates  that these animals 
remained immunocompetent, yet had donor-specific hypore- 
sponsiveness. In four of five rats, rejection of the BN skin 
grafts did not induce rejection of the BN hearts,  although 
it is notable that the single animal that rejected its primary 
Figure  1.  Histopathology  of cardiac tissue. Animals were treated with DST on day 0 plus CTLA4Ig on day 2, and hearts were removed for examina- 
tion at least 60 d after transplantation.  First cardiac allografrs appeared either  histologically normal (A) or showed evidence of focal rejection with 
resulting myocyte loss (B). In all cases, second cardiac aUografts showed no or minimal histologic evidence of rejection (C).  The native heart  from 
a LEW animal which received a BN ailograft is shown for comparison (D). The hearts were fixed in formalin and tissue sections were stained with 
hematoxylin  and eosin,  x100. 
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BN skin graft. 
Skin grafts are frequently rejected in animals tolerant to 
vascularized organs,  perhaps  because of the increased im- 
munogenicity of skin or the existence of skin-specific antigens 
(21). Second cardiac allografts from BN donors placed into 
CTLA4Ig plus DST-treated animals, all appeared to func- 
tion normally until the animals were killed for humane reasons. 
This occurred on days 17-52 after transplantation of the second 
heart. In all instances, histologic examination of the second 
heart revealed only minimal cellular infiltrates consistent with 
normal histology or focal mild rejection (Fig.  1). Consistent 
with  this  minimal response,  lymphocytes from engrafted 
animals have a 50% reduction in their in vitro proliferative 
response (as measured in an MLR) to donor-type stimulators 
(data not shown). This data is in agreement with our previous 
study which found a 50% decrease in MLR responsiveness 
to donor-type cells in CTLA4Ig-treated animals, with no effect 
on third-party responses (7). The reduction in proliferation 
appears to be somewhat modest, given the failure of the animals 
to reject their cardiac allografts grafts. This suggests either 
a discrepancy between in vitro and in vivo antidonor reac- 
tivity, or split tolerance characterized by CTL activity that 
is severely depressed in comparison with proliferative capacity. 
Together, our data indicate that DST at the time of cardiac 
transplantation followed by treatment with CTLA4Ig are 
sufficient to induce long-term cardiac allograft acceptance in 
rats.  These animals remain immunocompetent, but exhibit 
donor-specific nonresponsiveness. It should be emphasized 
that although the hearts remain functional as assessed by elec- 
trical activity and palpable contractions, some of the grafts 
have experienced focal rejection with resulting myocyte loss 
(Fig. 1 B). Thus long-term engraftment is not strictly equated 
with  immunologic nonresponsiveness.  However,  even  in 
animals with significant myocardial damage to their initial 
allograft, the second graft had minimal histologically abnor- 
malities, suggesting that a previously existing immune re- 
sponse might be relatively quiescent. 
A curious finding was that CTLA4Ig was dramatically more 
effective when given on day 2,  than on day 0.  Given that 
the half-life of CTLA4Ig is ;>60 h,  this finding cannot be 
due to the fact that when administered on day 0, the drug 
is absent by day 2. Rather, it suggests that the drug is most 
effective when given after an initial immune response is al- 
lowed to begin. The finding that a single dose of CTLA4Ig, 
without any DST, is more effective when administered at 
day 2 than at day 0 is consistent with this hypothesis. DST 
at day 0, which is also required for optimal graft prolonga- 
tion, may serve to help synchronize and/or maximally stimu- 
late the immune response by distributing alloantigen through- 
out  the  lymphoid  system.  Subsequent  treatment  with 
CTLA4Ig could then block costimulatory signals at at time 
when T  cells were maximally sensitive to this maneuver. 
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